Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis

被引:2
作者
Abdelwahab, Omar Ahmed [1 ,2 ]
Mechi, Ahmed [2 ,3 ]
Gahlan, Shereen [1 ,2 ]
Hamadein, Fatima-Elzahraa [4 ]
Kadhim, Hallas [2 ,5 ]
Ismail, Doaa [2 ,6 ]
Soliman, Youssef [2 ,7 ]
El-Samahy, Mohamed [2 ,6 ]
机构
[1] Al Azhar Univ, Fac Med, Cairo 11884, Egypt
[2] Med Res Grp Egypt, Cairo, Egypt
[3] Univ Kufa, Med Coll, Internal Med Dept, Najaf, Iraq
[4] Univ Gezira, Fac Med, Wad Madani, Sudan
[5] Al Muthanna Univ, Coll Med, Samawah, Iraq
[6] Zagazig Univ, Fac Med, ,El-Sharkia, Zagazig, Egypt
[7] Assiut Univ, Fac Med, Assiut, Egypt
关键词
Immune thrombocytopenic purpura; ITP; MMF; Mycophenolate mofetil; Systematic review; THERAPY; STANDARDIZATION; SPLENECTOMY; MECHANISMS; ANTIBODIES; MANAGEMENT; RESISTANT; RESPONSES; BIAS;
D O I
10.1007/s10067-023-06820-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundImmune thrombocytopenic purpura (ITP) is a challenging disease in its presentation and management as it may cause life-threatening hemorrhaging in vital organs and may resist several lines of treatment. This systematic review and meta-analysis aimed to evaluate the safety and efficacy of mycophenolate mofetil (MMF) in treating patients with ITP.MethodsWe systematically searched four electronic databases (PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials) from inception until 10 October 2022. We included all clinical trials, either controlled or single arm, and prospective and retrospective observational studies that evaluate the efficacy and safety of MMF in patients with ITP. We assessed the risk of bias using three tools (ROBINS-I, Cochrane ROB-2, and NIH), each for eligible study design.ResultsNine studies were included in this meta-analysis, with a total of 411 patients with ITP. We found that MMF demonstrated an overall response rate of (62.09%; 95% CI = [43.29 to 77.84]) and the complete response rate was (46.75%; 95% CI = [24.84 to 69.99]). The overall proportion of adverse events was (12%; 95% CI = [6 to 24]). After the sensitivity analysis, the overall response rate became 50%; 95% CI = [38 to 63]) and the complete response rate became (32%; 95% CI = [24 to 42]). However, MMF did not appear to affect white blood cell counts or hemoglobin levels significantly.ConclusionThis systematic review and meta-analysis demonstrate that MMF appears to be an effective and relatively safe treatment option for patients with ITP when combined with steroids and even in those who have not responded to standard therapies (steroid-resistant cases). Further research with well-designed studies is warranted to better understand the factors influencing treatment response and to refine the use of MMF in the management of ITP. An interactive version of our analysis can be accessed from here: https://databoard.shinyapps.io/mycophenolate_meta/
引用
收藏
页码:621 / 632
页数:12
相关论文
共 71 条
[1]   Why should we consider methotrexate in future trials of steroid-resistant immune thrombocytopenic purpura?-Correspondence [J].
Abdelwahab, Omar Ahmed ;
Seif, Ali Mohamed ;
Sherif, Mohamed El- Sebaey .
IMMUNOLOGY LETTERS, 2023, 254 :39-40
[2]  
Aghabeigi N, 2012, IRAN J PUBLIC HEALTH, V41, P53
[3]  
Al-Alfy M.N., 2015, Int J Intern Med, V2015, P14, DOI DOI 10.5923/J.IJIM.20150401.03
[4]   Mycophenolate suppresses inflammation by inhibiting prostaglandin synthases: a study of molecular and experimental drug repurposing [J].
Al-Hizab, Fahad ;
Kandeel, Mahmoud .
PEERJ, 2021, 9
[5]   Mycophenolate mofetil and its mechanisms of action [J].
Allison, AC ;
Eugui, EM .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :85-118
[6]  
Almizraq RJ., 2021, Ann Blood, V6, DOI [10.21037/aob-20-87, DOI 10.21037/AOB-20-87]
[7]  
[Anonymous], 2014, Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies
[8]   Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura [J].
Arnold, Donald M. ;
Nazi, Ishac ;
Santos, Aurelio ;
Chan, Howard ;
Heddle, Nancy M. ;
Warkentin, Theodore E. ;
Kelton, John G. .
BLOOD, 2010, 115 (01) :29-31
[9]   Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments [J].
Audia, Sylvain ;
Mahevas, Matthieu ;
Nivet, Martin ;
Ouandji, Sethi ;
Ciudad, Marion ;
Bonnotte, Bernard .
HEMASPHERE, 2021, 5 (06) :E574
[10]   Emerging Therapies in Immune Thrombocytopenia [J].
Audia, Sylvain ;
Bonnotte, Bernard .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) :1-19